Importantly, our observations were consistent in a hypoxic environment, emphasizing that the combination of reducing the activation threshold for NK activation by the selection of KIR-ligand-mismatched donors and maximizing NK cell activation with an ADCC-inducing antibody can potentiate the NK cell anti-breast cancer response. This evidence concerns the gene KIR3DL1 and breast cancer.